The second-largest selling drug worldwide could get some U.S. competition, according to an article in the Wall Street Journal. An FDA panel endorsed an alternative version of the current drug used to treat rheumatoid arthritis and other inflammatory diseases.
While not binding, the recommendation likely paves the way for FDA approval of the new drug. But it could take years to see those savings. Read the WSJ story